These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 20050366)

  • 1. Define "effective" the curious case of chronic cancer.
    Berlinger N; Flamm AL
    Hastings Cent Rep; 2009; 39(6):17-20. PubMed ID: 20050366
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical guidelines in advanced cancer: why we cannot avoid an evidence-based model.
    Tassinari D; Santelmo C; Tombesi P; Lazzari-Agli L; Sartori S
    Tumori; 2008; 94(4):622-3. PubMed ID: 18822708
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
    Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
    Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Communication near the end of life.
    De Padova S; Carlà G; Maniglia R; Salamina P; Lorusso V
    Tumori; 2008; 94(4):621; author reply 621-2. PubMed ID: 18822707
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-opportunity analysis in clinical oncology: from the 'wild far-west' to a correct integration of the disciplines, avoiding the 'war of the worlds'.
    Tassinari D; Poggi B; Fantini M; Tamburini E; Nicoletti S; Sartori S
    Ann Oncol; 2006 May; 17(5):876-7; reply 877-8. PubMed ID: 16317013
    [No Abstract]   [Full Text] [Related]  

  • 6. Not cost-effective at zero price: valuing and paying for combination therapies in cancer.
    Latimer NR; Towse A; Henshall C
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):331-333. PubMed ID: 33472440
    [No Abstract]   [Full Text] [Related]  

  • 7. Impact of uncertainty on cost-effectiveness analysis of medical strategies: the case of high-dose chemotherapy for breast cancer patients.
    Marino P; Siani C; Roché H; Moatti JP;
    Int J Technol Assess Health Care; 2005; 21(3):342-50. PubMed ID: 16110714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Not Available].
    Ackermann CJ; Güller U
    Ther Umsch; 2016 Nov; 73(9):511-514. PubMed ID: 27805490
    [No Abstract]   [Full Text] [Related]  

  • 9. The burdens of cancer therapy: clinical and economic outcomes of chemotherapy-induced mucositis.
    Rolston KV
    Cancer; 2004 Mar; 100(6):1324-5; author reply 1325-6. PubMed ID: 15022302
    [No Abstract]   [Full Text] [Related]  

  • 10. The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib.
    Carlson JJ; Canestaro W; Ravelo A; Wong W
    J Med Econ; 2017 Jul; 20(7):671-677. PubMed ID: 28332433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicare demonstration projects acknowledge evidence-based medicine in cancer care.
    Twombly R
    J Natl Cancer Inst; 2005 Jan; 97(1):6-7. PubMed ID: 15632369
    [No Abstract]   [Full Text] [Related]  

  • 12. [Thinking of oncology. Oncologic aspects in the report of the Hungarian Court of Auditors I].
    Telekes A
    Orv Hetil; 2008 Feb; 149(8):369-71. PubMed ID: 18281235
    [No Abstract]   [Full Text] [Related]  

  • 13. Financial Toxicity.
    Nogueira LA; Lenhani BE; Tomim DH; Kalinke LP
    Asian Pac J Cancer Prev; 2020 Feb; 21(2):289-293. PubMed ID: 32102501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Palliative care: an example of Comparative Effectiveness Research?].
    Schmacke N
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(7):484-91. PubMed ID: 22981024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Essentials for improving service quality in cancer care.
    Berry LL; Mate KS
    Healthc (Amst); 2016 Dec; 4(4):312-316. PubMed ID: 28007225
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
    Wu B; Chen H; Shen J; Ye M
    Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
    Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
    Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The nesting-egg problem: why comparative effectiveness research is trickier than it looks.
    Gilbert S
    Hastings Cent Rep; 2009; 39(6):11-4. PubMed ID: 20050363
    [No Abstract]   [Full Text] [Related]  

  • 20. Palliative chemotherapy.
    Ellison NM
    Am J Hosp Palliat Care; 1998; 15(2):93-103. PubMed ID: 9543897
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.